US Cerveau Technologies collaborates with Danish H Lundbeck A/S

Cerveau Technologies Inc has announced a research collaboration agreement with H Lundbeck A/S for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
The collaboration is focused on using [F-18]MK-6240 as a biomarker in Lundbeck neurodegenerative disease research studies. The parties will collaborate to evaluate ways to diagnose, prevent and evaluate new treatments for neurodegenerative diseases in humans.
“At Cerveau we are focused on enhancing access to key technologies that we believe have the potential to advance human health,” says Rick Hiatt, chief executive officer, Cerveau Technologies Inc. “We are excited by the opportunity to work with Lundbeck with the goal of expanding the availability of this novel investigational imaging agent to the broader scientific community.”
“There is a critical need for sensitive biomarkers to guide clinical development of new treatments for neurodegenerative diseases” says Mads Dalsgaard, Vice President of Clinical Development for H. Lundbeck A/S. “This collaboration with Cerveau is a great example of working together in a precompetitive fashion to accelerate the development of better therapies for patients with neurodegenerative disease such as Alzheimer’s.”
Cerveau Technologies Inc is a partnership between Enigma Biomedical Group Inc and Sinotau Pharmaceutical Group. Cerveau’s vision is globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer’s disease.